MX2022015535A - Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei. - Google Patents
Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei.Info
- Publication number
- MX2022015535A MX2022015535A MX2022015535A MX2022015535A MX2022015535A MX 2022015535 A MX2022015535 A MX 2022015535A MX 2022015535 A MX2022015535 A MX 2022015535A MX 2022015535 A MX2022015535 A MX 2022015535A MX 2022015535 A MX2022015535 A MX 2022015535A
- Authority
- MX
- Mexico
- Prior art keywords
- lactobacillus paracasei
- vesicles derived
- preventing
- mental
- treating neurological
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 6
- 241000186605 Lactobacillus paracasei Species 0.000 title abstract 5
- 208000012902 Nervous system disease Diseases 0.000 title abstract 4
- 208000025966 Neurological disease Diseases 0.000 title abstract 4
- 230000000926 neurological effect Effects 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011820 transgenic animal model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona con una composición para prevenir, mejorar o tratar un trastorno neurológico o trastorno mental que comprende vesículas derivadas de Lactobacillus paracasei como un ingrediente activo; los presentes inventores confirmaron que cuando las vesículas derivadas de Lactobacillus paracasei fueron administradas a un modelo animal transgénico de trastorno neurológico, anormalidades en la función de nervio cerebral se suprimen eficazmente y también confirmó que cuando las vesículas derivadas de Lactobacillus paracasei fueron administradas a un modelo animal de trastorno mental debido a estrés mental, las anormalidades en la función mental debido a estrés y los trastornos de comportamiento que acompañan fueron suprimidos eficazmente, de manera que las vesículas derivadas de Lactobacillus paracasei de conformidad con la presente invención pueden usarse de manera útil para el desarrollo de un farmacéutico o alimento funcional saludable para prevenir un trastorno neurológico o trastorno mental, mejorando los síntomas del mismo, o tratando el trastorno neurológico o trastorno mental y similares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200072685 | 2020-06-16 | ||
| KR1020200169167A KR102257130B1 (ko) | 2020-06-16 | 2020-12-07 | 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물 |
| PCT/KR2021/003075 WO2021256665A1 (ko) | 2020-06-16 | 2021-03-12 | 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015535A true MX2022015535A (es) | 2023-01-30 |
Family
ID=78824279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015535A MX2022015535A (es) | 2020-06-16 | 2021-03-12 | Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11672838B2 (es) |
| EP (1) | EP3957316B1 (es) |
| JP (2) | JP7385301B2 (es) |
| CN (1) | CN114144239B (es) |
| AU (1) | AU2021291569A1 (es) |
| BR (1) | BR112022025626A2 (es) |
| CA (1) | CA3181432A1 (es) |
| MX (1) | MX2022015535A (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021291569A1 (en) * | 2020-06-16 | 2022-10-20 | Md Healthcare Inc. | Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei |
| CN113322213B (zh) * | 2021-07-09 | 2022-05-13 | 吉林大学 | 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027956A2 (ko) * | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20130243728A9 (en) * | 2009-11-18 | 2013-09-19 | Agriculture Victoria Services Pty Ltd | Recombinant microorganisms |
| EP2675447A4 (en) * | 2011-02-18 | 2015-04-22 | Nestec Sa | METHODS AND COMPOSITIONS FOR TREATING, REDUCING OR PREVENTING DAMAGE TO THE NERVOUS ANIMAL SYSTEM |
| JPWO2015125878A1 (ja) * | 2014-02-24 | 2017-03-30 | 旭硝子株式会社 | 熱サイクルシステム用組成物および熱サイクルシステム |
| US9925225B2 (en) * | 2014-09-26 | 2018-03-27 | Nubiome, Inc. | Treatment and prophylaxis for gastroesophageal reflux disease |
| KR20170032815A (ko) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
| WO2017047962A1 (ko) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물 |
| WO2017074566A1 (en) * | 2015-10-30 | 2017-05-04 | Dean Falb | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| US10363279B2 (en) * | 2016-02-20 | 2019-07-30 | Nubiome, Inc. | Treatment and prophylaxis for neurological conditions and diseases |
| KR20180019474A (ko) | 2016-08-16 | 2018-02-26 | 주식회사 엠디헬스케어 | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
| KR101853603B1 (ko) * | 2017-05-18 | 2018-05-02 | 주식회사 쎌바이오텍 | 알코올 또는 아세트알데하이드 분해용 프로바이오틱스를 포함하는 조성물 |
| MA50086A (fr) * | 2017-09-08 | 2020-07-15 | Evelo Biosciences Inc | Vésicules extracellulaires (ev) bactériennes |
| EP3727410B1 (en) * | 2017-12-19 | 2024-06-12 | International N&H Denmark ApS | Probiotics for cognitive and mental health |
| WO2019119261A1 (en) * | 2017-12-19 | 2019-06-27 | Dupont Nutrition Biosciences Aps | Probiotics for cognitive and mental health |
| WO2019134690A1 (en) * | 2018-01-05 | 2019-07-11 | Bened Biomedical Co., Ltd. | A novel lactic acid bacteria and its applications |
| KR102101692B1 (ko) * | 2018-03-05 | 2020-04-20 | 주식회사 엠디헬스케어 | 락토바실러스 속 세균 유래 나노소포 및 이의 용도 |
| ES2954685T3 (es) * | 2018-06-01 | 2023-11-23 | Nzym Deutschland Gmbh | Microvesículas derivadas de productos de origen vegetal fermentados, método para su preparación y utilización |
| TWI718402B (zh) * | 2018-08-16 | 2021-02-11 | 葡萄王生技股份有限公司 | 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途 |
| US12036254B2 (en) * | 2018-10-26 | 2024-07-16 | Lac2biome S.r.l. | Bacterial strains of the Lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract |
| US10987386B2 (en) * | 2018-12-31 | 2021-04-27 | Md Healthcare Inc. | Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei |
| KR102098067B1 (ko) | 2018-12-31 | 2020-04-07 | 주식회사 엠디헬스케어 | 락토바실러스 파라카제이 유래 소포 및 이의 용도 |
| CN114728062A (zh) * | 2019-09-23 | 2022-07-08 | 密执安大学评议会 | 用于提高免疫疗法和疫苗功效的组合物和方法 |
| US20230000929A1 (en) * | 2019-11-26 | 2023-01-05 | Board Of Regents, The University Of Texas System | Bdellovibrio treatment for amyotrophic lateral sclerosis |
| AU2021291569A1 (en) * | 2020-06-16 | 2022-10-20 | Md Healthcare Inc. | Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei |
| KR102257130B1 (ko) * | 2020-06-16 | 2021-05-28 | 주식회사 엠디헬스케어 | 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물 |
-
2021
- 2021-03-12 AU AU2021291569A patent/AU2021291569A1/en active Pending
- 2021-03-12 BR BR112022025626A patent/BR112022025626A2/pt unknown
- 2021-03-12 EP EP21732162.9A patent/EP3957316B1/en active Active
- 2021-03-12 CA CA3181432A patent/CA3181432A1/en active Pending
- 2021-03-12 JP JP2021556268A patent/JP7385301B2/ja active Active
- 2021-03-12 MX MX2022015535A patent/MX2022015535A/es unknown
- 2021-03-12 CN CN202180001541.4A patent/CN114144239B/zh active Active
- 2021-06-10 US US17/343,901 patent/US11672838B2/en active Active
-
2023
- 2023-04-25 US US18/306,605 patent/US20230256040A1/en active Pending
- 2023-09-04 JP JP2023142644A patent/JP2023171724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022025626A2 (pt) | 2023-01-17 |
| CN114144239B (zh) | 2024-03-19 |
| US20210386800A1 (en) | 2021-12-16 |
| JP2023171724A (ja) | 2023-12-05 |
| AU2021291569A1 (en) | 2022-10-20 |
| EP3957316B1 (en) | 2024-02-07 |
| EP3957316A4 (en) | 2022-11-02 |
| US20230256040A1 (en) | 2023-08-17 |
| JP7385301B2 (ja) | 2023-11-22 |
| US11672838B2 (en) | 2023-06-13 |
| EP3957316C0 (en) | 2024-02-07 |
| CA3181432A1 (en) | 2021-12-23 |
| JP2022542734A (ja) | 2022-10-07 |
| CN114144239A (zh) | 2022-03-04 |
| EP3957316A1 (en) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015535A (es) | Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei. | |
| MY151018A (en) | Use of nutritional compositions for preventing disorders | |
| Savage | Epidemiology: The complexities of epilepsy. | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| WO2007110871A3 (en) | Methods and composition for treating sore throat | |
| TW200803865A (en) | Composition containing riboflavin and sesamins | |
| JP4669095B2 (ja) | ペットの問題行動抑制組成物 | |
| JP2019532926A5 (es) | ||
| MX2022011519A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. | |
| MX2022004382A (es) | Metodos para promover la produccion de scfa por microbiota intestinal. | |
| WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| US8017594B2 (en) | Agent against psychosocial stresses | |
| Levin et al. | Laughing headache: a novel type of triggered headache with response to divalproex sodium. | |
| ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
| JP2011178702A (ja) | 睡眠の改善剤 | |
| Chandrashekar et al. | Anxiolytic activity of ethanolic and aqueous extract of Ficus carica Linn. fruits in swiss albino mice | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| JP5963791B2 (ja) | 月経前症候群に付随する症状及び月経前不快気分障害を緩和するのに使用される組成物 | |
| JP7185260B2 (ja) | 悪夢障害の治療用医薬組成物 | |
| KR102651825B1 (ko) | 폴리코사놀을 유효성분으로 함유하는 기억 및 인지 기능 개선용 조성물 및 알츠하이머 예방 또는 개선용 조성물 |